Although the Oncology Care Model (OCM) is ending June 30, 2022, it does not mean practices can turn back the clock and revert to how they provided care prior to the OCM, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Just because the Oncology Care Model (OCM) is ending June 30, 2022, it does not mean practices can turn back the clock and revert to how they provided care prior to the OCM, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
On June 27, the Biden administration announced the new model that will replace OCM. The Enhancing Oncology Model will begin in July 2023.
Transcript
What do you expect practices will have to change with the OCM ending and a gap before the next model starts?
It is a challenge that OCM is scheduled to end here in June of 2022. We do anticipate that CMMI [Center for Medicare and Medicaid Innovation] will come out with either an OCM extension or a new model, the Oncology Care First model. I will say that the paradigm of cancer care has changed. We have made—and by we, I say Texas Oncology, have made—tens of millions of dollars of investments in infrastructure resources to deliver better cancer care.
Now, the findings of the specifics of OCM and the infrastructure investments that we’ve had is just how we deliver care today. And so, it’s almost impossible for me to think about divesting resources or changing the expectations of the level of care.
When we implemented OCM for our patient population, it wasn’t just for OCM patients. We made these changes for all of the patients at Texas Oncology. So, it’s hard to see going back. I do hope that CMMI comes to us with new innovative models that build upon what we’ve learned from OCM, because I think it’s better care for patients.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL
March 19th 2024The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment pf Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Read More